Trial Profile
A Phase 1, Open-Label, Dose-Ranging Study to Assess the Safety and Immunologic Activity of APN401
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 06 Nov 2021
Price :
$35
*
At a glance
- Drugs APN 401 (Primary)
- Indications Appendiceal cancer; Malignant melanoma; Pancreatic cancer; Renal cell carcinoma; Solid tumours
- Focus Adverse reactions; First in man; Therapeutic Use
- 14 Aug 2017 Status changed from active, no longer recruiting to completed.
- 07 Jun 2016 Results presented at the 52nd Annual Meeting of the American Society of Clinical Oncology
- 07 Jun 2016 Status changed from recruiting to active, no longer recruiting.